Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Other financing activities (2024)

Arrowhead Pharmaceuticals (ARWR) has disclosed Other financing activities for 6 consecutive years, with $5.0 million as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Other financing activities changed N/A year-over-year to $5.0 million, compared with a TTM value of $5.0 million through Sep 2025, up 59.54%, and an annual FY2025 reading of $5.0 million, up 59.54% over the prior year.
  • Other financing activities was $5.0 million for Q4 2024 at Arrowhead Pharmaceuticals, up from $3.1 million in the prior quarter.
  • Across five years, Other financing activities topped out at $5.0 million in Q4 2024 and bottomed at $3.1 million in Q3 2024.